AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.01 which represents a decrease of $-1.19 or -0.66% from the prior close of $179.2. The stock opened at $177.92 and touched a low of ...

This was the stock's second consecutive day of losses.

The stock's fall snapped a three-day winning streak.

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $180 which represents a slight increase of $1.61 or 0.90% from the prior close of $178.39. The stock opened at $178.41 and touched a low ...

Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Explore more ...

We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look ...

Schwab and Vanguard are both giants in the investment arena. Retirees who are considering between the two should base ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

The acquisition of Karuna Therapeutics Inc. by Bristol Myers Squibb Co. (BMS) was announced in December 2023, and closed as the BioEurope Spring meeting was convening in March. Along with the ...

Generating income has consistently been a primary goal for investors. To achieve this, they often opt for investments that provide steady and reliable returns over time.

The global cardiometabolic drugs market is projected to grow from US$ 50 billion in 2021 to over US$ 70 billion by 2032, with a CAGR of 4% to 5%. Sales are expected to surpass US$ 55 billion by 2022, ...

(RTTNews) - AbbVie Inc. (ABBV), Thursday announced that the Canadian Headache Society's newly updated Migraine Prevention Guideline has strongly supported the usage of Atogepant for episodic and ...